Selecta Bio up as gout treatment meets main goals in late-stage trials

Cartesian Therapeutics

21/03/2023 13:32

** Shares of drug developer Selecta Biosciences Inc  SELB.O 
up 8.6% at $1.4 before the bell 
    ** Co and partner Sobi report positive data from late-stage
trials in treating chronic refractory gout, a painful and severe
form of inflammatory arthritis 
    ** Safety and efficacy of SELB's therapy, SEL-212, at two
different doses meet primary goals in two trials 
    ** Co says response rate of 56% and 47% was recorded in
reducing excessive uric acid levels in blood, in patients
treated monthly with high dose SEL-212 in study trial 1 and 2,
respectively 
    ** In patients 50 years and older, response rate with high
dose SEL-212 was 65% and 48% in trial phases 
    ** Sobi licensed SEL-212 from SELB in June 2020 and is
responsible for development, regulatory and commercial
activities in all markets outside of China 
     ** Detailed results from both trial expected to be
presented at upcoming medical meeting 
    ** Co intends to file marketing authorization applications 
in U.S. in H1 of 2024 
    ** In 2022, co's stock fell 65.34%  

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))